Gilead, LEO Pharma partner to develop programs for inflammatory diseases
Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...
Gilead in pact for anti-inflammatory drugs in a deal worth up to $1.7B
Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.
Gilead upgraded by Morgan Stanley on lenacapavir potential
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...
Gilead Sciences Inc. stock outperforms competitors on strong trading day
The stock's rise snapped a five-day losing streak.
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors
This was the stock's fourth consecutive day of losses.
Hosted on MSN2d
Morgan Stanley Upgrades Gilead Sciences (GILD)
Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...
Harbor Capital Advisors Inc. Buys 616 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Harbor Capital Advisors Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.3% during the 4th ...
FierceBiotech1d
Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma
Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...
Gilead Sciences: Buy Rating Backed by Promising Pipeline and Attractive Valuation
Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...
Zacks.com on MSN3d
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.
ST Germain D J Co. Inc. Sells 571 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
ST Germain D J Co. Inc. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 15.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange ...
Business Wire1d
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO ...